Treats spasticity. ANDA 210021, held by Cadila Pharmaceuticals. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 210021 (Tizanidine Hydrochloride), held by Cadila Pharmaceuticals, was first approved by FDA on Mar 26, 2019, with 1 approved supplement and 0 published complete response letters.
Tizanidine Hydrochloride Capsules are indicated for the treatment of spasticity in adults. Tizanidine Hydrochloride Capsules are a central alpha-2-adrenergic agonist indicated for the treatment of spasticity.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 26, 2019 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 6MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| May 25, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 26, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters